Clinical Trials Logo
  1. Home
  2. Blepharoptosis
  3. NCT01848041

Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis

Blepharoptosis Clinical Trial

Official title:
A Randomized, Double-Masked, Placebo-Controlled Phase 1/2a Study of the Efficacy and Safety of Two Dosing Regimens of RVL-1201 in the Treatment of Acquired Blepharoptosis

Clinical Trial Summary

This is an exploratory, proof of concept study to evaluate the safety and efficacy of RVL-1201 dosed once or twice daily for 14 days compared to a placebo (vehicle) control in patients with ptosis.

Clinical Trial Description

This is an exploratory, proof-of-concept study. The objectives include establishing the efficacy and duration of effect of once daily (QD) or twice daily (BID) administration of RVL-1201 and the safety profile following 14 days of treatment in 72 subjects (24 per arm) with acquired blepharoptosis. Efficacy will be assessed at each treatment visit by the Humphrey Visual Field 36-point ptosis protocol test, photographic measurement of marginal reflex distance, palpebral fissure distance and contrast sensitivity in the study eye only and Visual Acuity assessment in both eyes. Safety assessments will include slit lamp examination/corneal fluorescein staining, pupil size measurement, ophthalmoscopy/ fundus examination, tonometry, visual acuity; urine pregnancy test (for women of childbearing potential only), vital signs (Heart Rate/Blood Pressure); and collection of adverse events. Subject rating of study medication comfort and assessment of ongoing tolerability will also be obtained. Primary efficacy endpoint is the mean increase from baseline in points seen on the HVF 36-point ptosis protocol test at various timepoints according to a hierarchical analysis. Analysis of exploratory endpoints will provide characterization of the efficacy and duration of effect of RVL-1201 with a variety of efficacy measures, as well as the potential additional effect of BID over QD dosing and safety profile of BID administration of RVL-1201. Exploratory endpoints will be analyzed by each regimen against placebo and between regimens and will include: - The change from baseline in HVF, MRD, PFD, VA, and CS. - The change from baseline in BP/HR ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01848041
Study type Interventional
Source RVL Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date May 2013
Completion date February 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT00864656 - Eyelid Position Interdependence in Involutional Ptosis Patients Submitted to 10% Phenylephrine N/A
Recruiting NCT02959697 - Subconjunctival Injection of Local Anesthetic in Anterior Blepharoptosis Repair N/A
Recruiting NCT02501187 - Risk of Dry Eye Post Different Surgeries for Blepharoptosis Repair N/A
Completed NCT00793988 - Vibration-Assisted Anaesthesia Phase 4
Completed NCT02367677 - Digital Photographs to Evaluate Blepharoptosis N/A
Recruiting NCT01239498 - Saline Injection - Assisted Anesthesia in Eyelid Surgery Phase 4
Not yet recruiting NCT05358977 - Fibrin Sealant in Eyelid Surgery Phase 2/Phase 3
Completed NCT01350024 - Comparison of Postoperative Pain With Two Different Types of Local Anesthesia in Surgery for a Drooping Eyelid N/A
Completed NCT06047418 - Blepharoptosis in Indonesia: A 5-Year Multicenter Study on Characteristics and Surgical Evaluation
Active, not recruiting NCT03149367 - Surgical Management of Blepharoptosis N/A
Completed NCT03565887 - Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis Phase 3
Recruiting NCT01968174 - Astigmatic Changes Secondary to Eyelid Surgeries N/A
Completed NCT03536949 - Study of Safety of RVL-1201 in Treatment of Blepharoptosis Phase 3
Recruiting NCT04678115 - Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis N/A
Not yet recruiting NCT04235803 - Telemedicine Follow-up for Routine, Low-Risk Oculoplastic Surgery N/A
Completed NCT02988856 - Magnetic Correction of Eye Lid Paralysis N/A
Terminated NCT03239418 - NMES to Improve Eyelid Functions in Cranial Nerve (CN) III and VII Palsy N/A
Not yet recruiting NCT02638610 - Assessment of Changes of Periocular Skin Sensation Following Eyelid and Ocular Surface Surgeries N/A
Enrolling by invitation NCT05945615 - Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis Phase 3
Recruiting NCT06292182 - Red Light Ptosis Proof-of-Concept N/A